Covidien plc (COV) Releases Results From First-in-Human Study of New Drug-Coated Balloon
5/24/2013 10:09:56 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PARIS--(BUSINESS WIRE)--Covidien, a leading global provider of healthcare products, announced the 12-month results from its ILLUMENATE First-in-Human (FIH) Study on the safety and effectiveness of Covidien’s advanced drug-coated balloon (DCB) technology at the EuroPCR Scientific Congress here. The new platform, featuring a paclitaxel-coated angioplasty balloon with a proprietary, rapid-release drug delivery mechanism, is designed to treat blockages in leg arteries caused by peripheral arterial disease (PAD).
Help employers find you! Check out all the jobs and post your resume.
comments powered by